Loading
A phase 1 trial of NKT5097 run by NiKang Therapeutics, Inc., now recruiting.
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors is a phase 1 interventional study registered as NCT07029399 by NiKang Therapeutics, Inc., with 361 participants planned, started 2025-03-25, primary completion expected 2027-07-31. Conditions recorded: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer. Interventions recorded: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/